Onconic Therapeutics Inc. (KOSDAQ:476060)
South Korea
· Delayed Price · Currency is KRW
21,900
-100 (-0.45%)
Apr 29, 2026, 3:30 PM KST
Onconic Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 53,392 | 14,838 | 21,056 | 95 | 60 |
| Revenue Growth (YoY) | 259.82% | -29.53% | 22064.25% | 58.33% | - |
| Cost of Revenue | 10.96 | 3.78 | 18,825 | 14,933 | 8,402 |
| Gross Profit | 53,381 | 14,835 | 2,231 | -14,838 | -8,342 |
| Selling, General & Admin | 30,370 | 8,087 | - | - | - |
| Research & Development | 9,721 | 10,929 | - | - | - |
| Amortization of Goodwill & Intangibles | 1.18 | 1.18 | - | - | - |
| Other Operating Expenses | 142.77 | 164.15 | - | - | - |
| Operating Expenses | 40,762 | 19,632 | - | - | - |
| Operating Income | 12,619 | -4,798 | 2,231 | -14,838 | -8,342 |
| Interest Expense | -11.68 | -664.16 | -2,522 | -1,078 | -6,831 |
| Interest & Investment Income | 1,387 | 942.63 | 938.61 | 1,431 | 18.85 |
| Currency Exchange Gain (Loss) | -282.81 | 2,020 | - | - | - |
| Other Non Operating Income (Expenses) | 1.65 | -7,442 | 14.72 | 52.86 | 5.74 |
| EBT Excluding Unusual Items | 13,713 | -9,942 | 661.8 | -14,432 | -15,149 |
| Gain (Loss) on Sale of Investments | 10.77 | - | - | - | - |
| Pretax Income | 13,724 | -9,942 | 661.8 | -14,432 | -15,149 |
| Income Tax Expense | -2,060 | -1,849 | -1,021 | - | - |
| Net Income | 15,784 | -8,093 | 1,682 | -14,432 | -15,149 |
| Net Income to Common | 15,784 | -8,093 | 1,682 | -14,432 | -15,149 |
| Shares Outstanding (Basic) | - | 33 | 23 | 23 | 23 |
| Shares Outstanding (Diluted) | - | 33 | 23 | 23 | 23 |
| Shares Change (YoY) | - | 41.46% | -0.00% | 0.94% | - |
| EPS (Basic) | - | -247.45 | 72.78 | -624.23 | -661.40 |
| EPS (Diluted) | - | -247.45 | 72.78 | -624.23 | -661.40 |
| Free Cash Flow | 11,092 | -7,982 | 2,988 | -17,536 | -8,861 |
| Free Cash Flow Per Share | - | -244.07 | 129.24 | -758.49 | -386.90 |
| Gross Margin | 99.98% | 99.98% | 10.60% | - | - |
| Operating Margin | 23.64% | -32.33% | 10.60% | -15618.48% | -13903.24% |
| Profit Margin | 29.56% | -54.54% | 7.99% | -15191.48% | -25247.72% |
| Free Cash Flow Margin | 20.77% | -53.79% | 14.19% | -18458.96% | -14769.11% |
| EBITDA | 13,148 | -4,345 | 2,541 | -14,770 | -8,292 |
| EBITDA Margin | 24.63% | -29.28% | 12.07% | - | - |
| D&A For EBITDA | 528.44 | 452.67 | 309.77 | 67.43 | 49.65 |
| EBIT | 12,619 | -4,798 | 2,231 | -14,838 | -8,342 |
| EBIT Margin | 23.64% | -32.33% | 10.60% | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.